NCT05768919: An ongoing trial by SignPath Pharma, Inc.
This trial is ongoing. It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05768919 |
|---|---|
| Title | Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 3, 2023 |
| Completion date | Feb. 28, 2026 |
| Required reporting date | Feb. 28, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |